Effects of SARS-CoV-2 P.1 variant to therapeutic antibodies and SARS-CoV-2 vaccines 

A group from University of Oxford, etc. has reported the effects of P.1 variant to therapeutic antibodies and SARS-CoV-2 vaccines.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008340/

P.1 contains the following mutations:
L18F, T20N, P26S, D138Y, and R190S in the NTD;
K417T, E484K, and N501Y in the RBD;
D614G and H655Y at the C terminus of S1;
and T1027I and V1176F in S2

Neutralization of both Lilly antibodies (LY-CoV16 and LY-CoV555) was severely impacted. There was also escape from neutralization of P.1 by Regeneron antibody (REGN10933) and a modest reduction in neutralization of P.1 by AstraZeneca antibody (AZD8895), while AstraZeneca antibodies (AZD1061 and AZD 7442) showed equal neutralization of all SARS-CoV-2 variants. The three Adagio antibodies (ADG10, ADG20, and ADG30) neutralized all variants, with all reaching a plateau at 100% neutralization; interestingly, ADG30 showed a slight increase of neutralization of P.1.

Geometric mean neutralization titers against P.1 were reduced 2.6-fold (p < 0.0001) relative to the Victoria virus for the Pfizer-BioNTech vaccine serum and 2.9-fold (p < 0.0001) for the Oxford-AstraZeneca vaccine.